Merck adds third cervical cancer nod for Keytruda, bringing total approvals to 39

Mer­ck’s Keytru­da scored its third US ap­proval in cer­vi­cal can­cer, mak­ing it the first and on­ly an­ti-PD-1 ther­a­py ap­proved as a com­bi­na­tion with chemora­dio­ther­a­py for pa­tients with FI­GO 2014 stage III-IVA cer­vi­cal can­cer.

The FDA added an­oth­er in­di­ca­tion to Mer­ck’s block­buster based on da­ta from the 1,060-pa­tient Phase III KEYNOTE-A18 tri­al. In the study, the com­bi­na­tion re­duced the risk of dis­ease pro­gres­sion or death by 41% com­pared to place­bo plus chemora­dio­ther­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.